MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326686 | Name: Fenspiride HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. The pharmacotherapeutic classification is antitussives. In Russia it is approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.

Chemical Structure

Fenspiride HCl
Fenspiride HCl
CAS#5053-08-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 326686

Name: Fenspiride HCl

CAS#: 5053-08-7 (HCl)

Chemical Formula: C15H21ClN2O2

Exact Mass: 0.0000

Molecular Weight: 296.80

Elemental Analysis: C, 60.70; H, 7.13; Cl, 11.94; N, 9.44; O, 10.78

Price and Availability

Size Price Availability Quantity
5g USD 350.00 2 Weeks
10g USD 550.00 2 Weeks
25g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
5053-08-7 (HCl) 5053-06-5 (free base)
Synonym
JP 428; JP428; JP-428; NAT-333; NAT333; NAT 333; NDR-5998A; NDR 5998A; NDR5998A; Decaspiride; Espiran; Fenspiride HCl; Fenspiride hydrochloride; Fluiden. brand names Eurespal, Pneumorel
IUPAC/Chemical Name
8-(2-Phenylethyl)-1-oxa-3,8-diazaspiro(4.5)decan-2-one hydrochloride
InChi Key
FIKFLLIUPUVONI-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H20N2O2.ClH/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13;/h1-5H,6-12H2,(H,16,18);1H
SMILES Code
O=C1OC2(CCN(CCC3=CC=CC=C3)CC2)CN1.[H]Cl
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 296.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fedin AV. [The assessment of the clinical effectiveness of fenspiride for the treatment of acute obstruction of the Eustachian tube]. Vestn Otorinolaringol. 2015;(1):70-1. Russian. PubMed PMID: 25909681. 2: Mel'chinskiĭ AN, Vasilenko DIu, Kiseleva GV. [The assessment of the effectiveness of fenspiride (erespal) for the combined treatment of the patients presenting with exudative otitis media]. Vestn Otorinolaringol. 2013;(6):70-1. Russian. PubMed PMID: 24429863. 3: Kuzubova NA, Lebedeva ES, Fedin AN, Dvorakovskaya IV, Preobrazhenskaya TN, Titova ON. Effect of fenspiride on bronchial smooth muscle of rats with chronic obstructive pulmonary disease. J Smooth Muscle Res. 2013;49:46-54. PubMed PMID: 24133694. 4: Kuzubova NA, Lebedeva ES, Fedin AN, Dvorakovskaya IV, Titova ON. Protective effect of fenspiride on the bronchi in rats with chronic obstructive pulmonary disease. Bull Exp Biol Med. 2013 Jun;155(2):214-7. PubMed PMID: 24130993. 5: Lebedenko AA, Mal'tsev SV. [The efficacy of application of fenspiride (erespal) for the treatment of exacerbation of bronchial asthma in children]. Vestn Otorinolaringol. 2011;(4):66-7. Russian. PubMed PMID: 21983674. 6: Medvedovici A, Udrescu S, Albu F, Tache F, David V. Large-volume injection of sample diluents not miscible with the mobile phase as an alternative approach in sample preparation for bioanalysis: an application for fenspiride bioequivalence. Bioanalysis. 2011 Sep;3(17):1935-47. doi: 10.4155/bio.11.148. PubMed PMID: 21899503. 7: Baryshevskaia LA, Velikanov AK, Sedykh MI. [Experience with fenspiride in a rhinosurgeon's practice]. Vestn Otorinolaringol. 2009;(2):46-8. Russian. PubMed PMID: 19491799. 8: Afon'kin VIu, Dobretsov KG, Sipkin AV. [Hearing rehabilitation in patients with acute otitis media treated with fenspiride]. Vestn Otorinolaringol. 2008;(1):59-60. Russian. PubMed PMID: 18454061. 9: Butorov SI, Butorov IV, Bodrug NI, Krushka SI, Tofan EF. [Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride]. Ter Arkh. 2008;80(3):24-8. Russian. PubMed PMID: 18441679. 10: Butorov SI, Muntianu VI. [The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease]. Klin Med (Mosk). 2007;85(5):43-7. Russian. PubMed PMID: 17665604. 11: Volkova LI, Budkova AA, Filonova NN, Khristolyubova EI, Kutuzova EB, Koroleva NV, Radzivil TT, Aminova ZR, Chuchalin AG. Efficacy of supplemental anti-inflammatory therapy with fenspiride in chronic obstructive and nonobstructive bronchitis. Clin Drug Investig. 2005;25(4):257-64. PubMed PMID: 17523776. 12: Shmelev EI, Kunicina YL. Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease. Clin Drug Investig. 2006;26(3):151-9. PubMed PMID: 17163246. 13: Pirozyński M, Skucha W, Słomiński M, Chyczewska E, Malinowski J, Nowak D, Bartmińiski W, Pachocki R; Badawczej Robert Pachocki -w Imieniu Grupy. [The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis]. Pol Merkur Lekarski. 2005 Aug;19(110):139-43. Polish. PubMed PMID: 16245418. 14: Płusa T, Ochwat A. [Fenspiride in patients with acute bronchitis]. Pol Merkur Lekarski. 2005 Jul;19(109):32-6. Polish. PubMed PMID: 16194023. 15: Zielnik-Jurkiewicz B, Jurkiewicz D. [Usefulness of fenspiride in the treatment of acute otitis media in children]. Pol Merkur Lekarski. 2005 Jun;18(108):624-8. Polish. PubMed PMID: 16124370. 16: Zawisza E. [Effectiveness and tolerance of fenspiride treatment in chronic sinusitis. Results of the Polish multicenter study]. Otolaryngol Pol. 2005;59(1):141-5. Polish. PubMed PMID: 15915935. 17: Chodorowski Z, Sein Anand J, Korolkiewicz R. [Acute intoxication with fenspiride]. Przegl Lek. 2004;61(4):435-6. Polish. PubMed PMID: 15521623. 18: Mihălţan F. [Fenspiride-a new alternative on the therapy of obstructive lung disease]. Pneumologia. 2003 Apr-Jun;52(2):123-5. Review. Romanian. PubMed PMID: 14702716. 19: Jankowski R. [ENT inflammation and importance of fenspiride]. Presse Med. 2002 Sep;31 Spec No 1:HS7-10. French. PubMed PMID: 12378970. 20: Melloni B. [Bronchial inflammation during chronic bronchitis, importance of fenspiride]. Presse Med. 2002 Sep;31 Spec No 1:HS11-5. French. PubMed PMID: 12378968.